ZA976326B - Analogs of cationic proteins. - Google Patents
Analogs of cationic proteins.Info
- Publication number
- ZA976326B ZA976326B ZA9706326A ZA976326A ZA976326B ZA 976326 B ZA976326 B ZA 976326B ZA 9706326 A ZA9706326 A ZA 9706326A ZA 976326 A ZA976326 A ZA 976326A ZA 976326 B ZA976326 B ZA 976326B
- Authority
- ZA
- South Africa
- Prior art keywords
- analogs
- cationic proteins
- cationic
- proteins
- Prior art date
Links
- 125000002091 cationic group Chemical group 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factors [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factors [FGF]
- C07K14/503—Fibroblast growth factors [FGF] basic FGF [bFGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68435396A | 1996-07-19 | 1996-07-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA976326B true ZA976326B (en) | 1998-02-03 |
Family
ID=24747700
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA9706326A ZA976326B (en) | 1996-07-19 | 1997-07-17 | Analogs of cationic proteins. |
Country Status (11)
Country | Link |
---|---|
US (4) | US6211150B1 (xx) |
EP (1) | EP0938499A1 (xx) |
AU (1) | AU720232B2 (xx) |
CA (1) | CA2259163C (xx) |
CZ (1) | CZ399A3 (xx) |
IL (1) | IL127872A0 (xx) |
NO (1) | NO990059L (xx) |
NZ (1) | NZ333650A (xx) |
SK (1) | SK1499A3 (xx) |
WO (1) | WO1998003546A1 (xx) |
ZA (1) | ZA976326B (xx) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1284143A1 (en) * | 2001-08-17 | 2003-02-19 | Sifi S.p.A | A process for the preparation of pharmaceutical formulations containing lactoferrin description |
RS54160B1 (sr) | 2003-03-19 | 2015-12-31 | Biogen Idec Ma Inc. | Protein koji se vezuje za nogo receptor |
US8597911B2 (en) | 2003-06-11 | 2013-12-03 | Chugai Seiyaku Kabushiki Kaisha | Process for producing antibodies |
WO2005035753A1 (ja) | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
EP1720564A1 (en) * | 2004-02-20 | 2006-11-15 | Rinat Neuroscience Corp. | Methods of treating obesity or diabetes using nt-4/5 |
CA2572193A1 (en) | 2004-06-24 | 2006-01-05 | Biogen Idec Ma Inc. | Treatment of conditions involving oligodendrocytes with sp35 based agents |
US7476331B2 (en) * | 2005-02-09 | 2009-01-13 | E I Du Pont Nemours And Company | Compositions comprising 1,1,1,2,2,3,4,5,5,6,6,7,7,7-tetradecafluoroheptane and uses thereof |
WO2006106905A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | 会合制御によるポリペプチド製造方法 |
AU2006255101A1 (en) | 2005-06-06 | 2006-12-14 | Wyeth | Anti-TrkB monoclonal antibodies and uses thereof |
EP2238986A3 (en) | 2005-07-08 | 2010-11-03 | Biogen Idec MA Inc. | Sp35 antibodies and uses thereof |
WO2007058843A2 (en) * | 2005-11-15 | 2007-05-24 | Lentigen Corporation | Web based vector design |
US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
ES2568436T3 (es) * | 2006-03-31 | 2016-04-29 | Chugai Seiyaku Kabushiki Kaisha | Procedimiento para controlar la farmacocinética en sangre de anticuerpos |
EP3689912A1 (en) * | 2007-09-26 | 2020-08-05 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
SG10201605394SA (en) | 2007-09-26 | 2016-08-30 | Chugai Pharmaceutical Co Ltd | Modified Antibody Constant Region |
BRPI0817637A2 (pt) * | 2007-09-28 | 2015-09-08 | Chugai Pharmaceutical Co Ltd | anticorpo anti-glipican-3 tendo cinéticas aperfeiçoadas no plasma |
CN101980603A (zh) * | 2007-10-11 | 2011-02-23 | 比奥根艾迪克Ma公司 | LINGO-1和TrkB拮抗剂的用途 |
CN101918540B (zh) * | 2007-11-08 | 2016-05-11 | 比奥根Ma公司 | Lingo-4拮抗剂在治疗涉及脱髓鞘的疾患中的应用 |
RU2531521C2 (ru) | 2007-12-05 | 2014-10-20 | Чугаи Сейяку Кабусики Кайся | Антитело против nr10 и его применение |
EP4238993A3 (en) | 2008-04-11 | 2023-11-29 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
AU2009269099B2 (en) | 2008-07-09 | 2016-03-10 | Biogen Ma Inc. | Compositions comprising antibodies to LINGO or fragments thereof |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
JP5787446B2 (ja) | 2009-03-19 | 2015-09-30 | 中外製薬株式会社 | 抗体定常領域改変体 |
WO2010131733A1 (ja) | 2009-05-15 | 2010-11-18 | 中外製薬株式会社 | 抗axl抗体 |
EP2481752B1 (en) | 2009-09-24 | 2016-11-09 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
JP5889181B2 (ja) | 2010-03-04 | 2016-03-22 | 中外製薬株式会社 | 抗体定常領域改変体 |
MY166429A (en) | 2010-11-17 | 2018-06-26 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
SG190727A1 (en) | 2010-11-30 | 2013-07-31 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
KR102147548B1 (ko) | 2011-02-25 | 2020-08-24 | 추가이 세이야쿠 가부시키가이샤 | FcγRIIb 특이적 Fc 항체 |
TW201817745A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
JP2015518829A (ja) | 2012-05-14 | 2015-07-06 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | 運動ニューロンに関する状態の処置のためのlingo−2アンタゴニスト |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
WO2014144817A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Inhibitory polypeptides specific to wnt inhibitors |
JP6668241B2 (ja) | 2013-09-05 | 2020-03-18 | アムジエン・インコーポレーテツド | 予測可能で、一貫性のある、且つ再現可能な糖型特性を示すFc含有分子 |
KR102441231B1 (ko) | 2013-09-27 | 2022-09-06 | 추가이 세이야쿠 가부시키가이샤 | 폴리펩티드 이종 다량체의 제조방법 |
EP3467501B1 (en) | 2014-05-16 | 2020-11-04 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
TWI808330B (zh) | 2014-12-19 | 2023-07-11 | 日商中外製藥股份有限公司 | 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法 |
SG11201607165YA (en) | 2014-12-19 | 2016-09-29 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
CA2973266A1 (en) | 2015-01-08 | 2016-07-14 | Biogen Ma Inc. | Lingo-1 antagonists and uses for treatment of demyelinating disorders |
TW202248212A (zh) | 2015-02-05 | 2022-12-16 | 日商中外製藥股份有限公司 | 包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途 |
TW202339800A (zh) | 2015-02-27 | 2023-10-16 | 日商中外製藥股份有限公司 | Il-6受體抗體用於製備醫藥組成物的用途 |
EP3279216A4 (en) | 2015-04-01 | 2019-06-19 | Chugai Seiyaku Kabushiki Kaisha | PROCESS FOR PREPARING POLYPEPTIDE HETERO OLIGOMER |
JP7023461B2 (ja) | 2015-07-28 | 2022-02-22 | オトノミ―,インク. | 耳の疾病の処置のためのtrkb又はtrkcアゴニスト組成物及び方法 |
US10066229B2 (en) | 2015-07-28 | 2018-09-04 | Otonomy, Inc. | Treatment using truncated Trk B and Trk C antagonists |
EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE |
AU2016381992B2 (en) | 2015-12-28 | 2024-01-04 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
AU2017233658B2 (en) | 2016-03-14 | 2023-09-21 | Chugai Seiyaku Kabushiki Kaisha | Cell injury inducing therapeutic drug for use in cancer therapy |
KR20190024983A (ko) | 2016-06-29 | 2019-03-08 | 오토노미, 인코포레이티드 | 트리글리세라이드 귀 제제 및 이의 용도 |
EP3494991A4 (en) | 2016-08-05 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATING TO IL-8 |
EP3596225A1 (en) | 2017-03-14 | 2020-01-22 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
EA202092286A1 (ru) | 2018-03-26 | 2021-03-18 | Эмджен Инк. | Общие афукозилированные гликоформы антител, полученные в культуре клеток |
EP4034556A1 (en) | 2019-09-26 | 2022-08-03 | Amgen Inc. | Methods of producing antibody compositions |
US20230273126A1 (en) | 2020-06-04 | 2023-08-31 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
WO2022081824A1 (en) | 2020-10-15 | 2022-04-21 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
AR126089A1 (es) | 2021-06-07 | 2023-09-13 | Amgen Inc | Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas |
AU2022361382A1 (en) | 2021-10-05 | 2024-03-28 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5322678A (en) * | 1988-02-17 | 1994-06-21 | Neorx Corporation | Alteration of pharmacokinetics of proteins by charge modification |
US6247647B1 (en) * | 1988-09-19 | 2001-06-19 | Symbol Technologies, Inc. | Scan pattern generator convertible between multiple and single line patterns |
US5229500A (en) * | 1989-08-30 | 1993-07-20 | Regeneron Pharmaceuticals, Inc. | Brain derived neurotrophic factor |
JPH0595786A (ja) | 1991-10-07 | 1993-04-20 | Green Cross Corp:The | 変異ヒトプロウロキナーゼ |
US5349055A (en) * | 1992-03-06 | 1994-09-20 | Persson Hakan B | Nerve growth factor having altered receptor binding specificities |
SG79882A1 (en) * | 1994-02-14 | 2001-04-17 | Kirin Brewery | Protein having tpo activity |
ES2196088T3 (es) * | 1994-10-13 | 2003-12-16 | Amgen Inc | Analogos del factor de crecimiento de los queratinocitos. |
US5770577A (en) * | 1994-11-14 | 1998-06-23 | Amgen Inc. | BDNF and NT-3 polypeptides selectively linked to polyethylene glycol |
US5830857A (en) * | 1995-07-14 | 1998-11-03 | Amgen Inc. | Method of treating epilepsy |
-
1997
- 1997-07-17 SK SK14-99A patent/SK1499A3/sk unknown
- 1997-07-17 AU AU36712/97A patent/AU720232B2/en not_active Ceased
- 1997-07-17 CA CA002259163A patent/CA2259163C/en not_active Expired - Fee Related
- 1997-07-17 ZA ZA9706326A patent/ZA976326B/xx unknown
- 1997-07-17 US US09/214,214 patent/US6211150B1/en not_active Expired - Fee Related
- 1997-07-17 WO PCT/US1997/012609 patent/WO1998003546A1/en not_active Application Discontinuation
- 1997-07-17 CZ CZ993A patent/CZ399A3/cs unknown
- 1997-07-17 EP EP97933550A patent/EP0938499A1/en not_active Withdrawn
- 1997-07-17 IL IL12787297A patent/IL127872A0/xx unknown
- 1997-07-17 NZ NZ333650A patent/NZ333650A/en unknown
-
1999
- 1999-01-07 NO NO990059A patent/NO990059L/no unknown
-
2000
- 2000-12-19 US US09/742,600 patent/US6723701B2/en not_active Expired - Fee Related
- 2000-12-19 US US09/745,032 patent/US6500429B2/en not_active Expired - Fee Related
-
2003
- 2003-07-11 US US10/618,283 patent/US20050143294A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2259163A1 (en) | 1998-01-29 |
EP0938499A1 (en) | 1999-09-01 |
CZ399A3 (cs) | 1999-06-16 |
US6211150B1 (en) | 2001-04-03 |
NO990059D0 (no) | 1999-01-07 |
IL127872A0 (en) | 1999-10-28 |
AU3671297A (en) | 1998-02-10 |
US6500429B2 (en) | 2002-12-31 |
US6723701B2 (en) | 2004-04-20 |
AU720232B2 (en) | 2000-05-25 |
NZ333650A (en) | 2000-02-28 |
WO1998003546A1 (en) | 1998-01-29 |
NO990059L (no) | 1999-03-19 |
CA2259163C (en) | 2004-07-06 |
SK1499A3 (en) | 1999-08-06 |
US20050143294A1 (en) | 2005-06-30 |
US20020010135A1 (en) | 2002-01-24 |
US20010027179A1 (en) | 2001-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA976326B (en) | Analogs of cationic proteins. | |
HUP9904239A3 (en) | High level expression of proteins | |
ZA9710338B (en) | Proteins | |
GB9510830D0 (en) | Proteins | |
GB9719879D0 (en) | Protein | |
GB9703681D0 (en) | Protein complemention | |
EP1018551A4 (en) | MEGSINE PROTEIN | |
ZA984322B (en) | Sucrose-binding proteins | |
IL115317A0 (en) | Proteins | |
GB9715064D0 (en) | Protein expression | |
GB9413316D0 (en) | Novel proteins | |
GB9720784D0 (en) | Protein | |
IL156970A0 (en) | Analogs of cationic proteins | |
EP0915100A4 (en) | NEW PROTEIN | |
ZA975001B (en) | Preparation of Alpha-fluoroketones. | |
ZA971900B (en) | Modified proteins | |
GB9703850D0 (en) | Novel protein | |
GB9714075D0 (en) | Novel protein | |
GB9706119D0 (en) | Novel protein | |
GB9703827D0 (en) | Novel protein | |
GB9704252D0 (en) | Novel protein | |
GB9703104D0 (en) | Proteins | |
GB9722003D0 (en) | Proteins | |
GB9722727D0 (en) | Proteins | |
GB9707822D0 (en) | Proteins |